Semaglutide

Semaglutide is a GLP‑1 receptor agonist originally developed by Novo Nordisk and FDA‑approved for type 2 diabetes and obesity; community reports show it is most often used for weight management, broader metabolic health, and type 2 diabetes control. Typical self‑dose clusters near 250 µg daily (reported range 50 µg–25 mg), clinician regimens usually use 0.5–1 mg oral per day, while timing and cycling are not consistently reported; side effects are only occasional, with edema, injection‑site reactions, nausea/GI issues, and sleep‑related changes each appearing in a small share of reports, and the off‑label evidence base remains thinner than the discourse suggests because most exploratory indications lack posted results.

Half-life~7 days

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsAnecdotalEfficacyAnecdotalSideEffectsPrice3.74.81.34.42.13.0

Research Evidence

Evidence shape

Semaglutide has high‑level evidence for treating type 2 diabetes and obesity, based on numerous human treatment studies. Of the 490 registered trials, 242 are completed and 79 have posted results, involving 63 distinct sponsors and 58 blinded trials with data, while adverse‑event rows are aggregated from 74 trials, across 167 indications, only 13 of which have any posted outcomes. Meanwhile, 150 indications stay thin or exploratory, 124 rely on a single trial without posted results, one indication remains animal‑only, and most of the completed trials still lack published results.

Depthhow much
497 registered trials
247 completed · 69 with posted results · 206 recruiting / active · combined n=67068
Breadthhow many areas
163 indications mapped
11 with results · 150 thin / exploratory · 1 animal-only · 118 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
45 blinded with results · 59 distinct sponsors · AE rows aggregated from 66 trials · 27 linked publications on registered trials
Breadth and depth527 rows captured
Human
direct clinical signal
512
Animal
translational support
12
In vitro
mechanistic support
3
HighMediumLow

Anecdotal efficacy

Semaglutide side effects

Clinical research side effects

Anecdotal side effects

Price

Full buying guide →
1
Chimera Peptides
CN
300 mg×10
$139.00
$0.46/mg
2
Mrbeetoe
--
50 mg
$40.00
$0.8/mg
3
Uther
unknown
200 mg×10
$170.00
$0.85/mg
4
Synagenics LLC
--
30 mg
$50.00
$1.67/mg
5
BulkGLP
USA
1000 mg
$1,699.00
$1.7/mg
6
Ironaminos
US
20 mg
$34.99
$1.75/mg

price offers can be sorted by column

1-6 of 168

Semaglutide dosing & protocol

How Semaglutide is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 258
Typical dose
2.4 mg500 µg – 50 mg
typical
0
10 mg
20 mg
30 mg
40 mg
50 mg
distribution of 116 reported doses · darker = more
Frequency
weekly
Route
subQ

In research trials, semaglutide has been used at doses ranging from 0.5 mg to 50 mg, most often 2.4 mg subcutaneously once weekly.

258 sources
Clinician practice
Doctor & published-protocol guidance · n = 2
Typical dose
500 µg500 µg – 1 mg
typical
0
10 mg
20 mg
30 mg
40 mg
50 mg
distribution of 4 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
daily
Route
oral

The clinician practice tier reports an oral dose of 500 mcg daily, with a reported range of 500 mcg to 1 mg per day.

2 sources
Anecdotal
Community-reported real-world use · n = 98
Typical dose
250 µg50 µg – 25 mg
typical
0
10 mg
20 mg
30 mg
40 mg
50 mg
distribution of 109 reported doses · darker = more
By stated route· tap a row to filter the chart
Frequency
unspecified
Route
subQ

Community users typically report a dose around 250 mcg subcutaneously, though reported amounts span from 50 mcg up to 25 mg; dosing frequency and cycling patterns were not specified in the data.

98 sources

Regulatory safety notes

Warnings and precautions
  • • Acute Pancreatitis : Has been observed in patients treated with GLP-1 receptor agonists, including RYBELSUS or OZEMPIC tablets. Discontinue if pancreatitis is suspected. •
  • • Diabetic Retinopathy Complications : Has been reported in a cardiovascular outcomes trial with semaglutide injection. Patients with a history of diabetic retinopathy should be monitored. •
  • • Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin : May increase the risk of hypoglycemia, including severe hypoglycemia. Reducing the dosage of insulin secretagogue or insulin may be necessary. •
  • • Acute Kidney Injury Due to Volume Depletion : Monitor renal function in patients reporting adverse reactions that could lead to volume depletion. •
  • • Severe Gastrointestinal Adverse Reactions : Use of RYBELSUS or OZEMPIC tablets has been associated with gastrointestinal adverse reactions, sometimes severe. RYBELSUS and OZEMPIC tablets are not recommended in patients with severe gastroparesis. •
  • • Hypersensitivity Reactions : Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue RYBELSUS or OZEMPIC tablets if hypersensitivity reactions occur and monitor until signs and symptoms resolve. •
  • • Acute Gallbladder Disease : If cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated. •
  • • Pulmonary Aspiration During General Anesthesia or Deep Sedation : Has been reported in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures. Instruct patients to inform healthcare providers of any planned surgeries or procedu…
Contraindications
  • • RYBELSUS and OZEMPIC tablets are contraindicated in
  • • patients with: • A personal or family history of medullary thyroid carcinoma (MTC) or in
  • • patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions (5.1) ] . • A prior serious hypersensitivity reaction to semaglutide or to any of the excipients in RYBELSUS or OZEMPIC ta…
  • • patients with MEN 2 syndrome type 2 • Prior serious hypersensitivity reaction to semaglutide or any of the excipients in OZEMPIC
Drug interactions
  • • Drugs : RYBELSUS and OZEMPIC tablets delay gastric emptying. Consider increased clinical or laboratory monitoring when co-administered with other oral medications that have a narrow therapeutic index or that require clinical monitoring. (7.2)

Related peptides

TirzepatideRetatrutideSurvodutideAOD-9604CagrilintideOrforglipronLiraglutideExenatideTesamorelinEloralintideTesofensineMazdutide